The Share

The Diamyd Medical share is traded on NASDAQ Stockholm First North (ticker : DMYD B).

About First North

First North is an alternative marketplace operated by an exchange within the NASDAQ OMX group. Companies on First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on First North may therefore be higher than investing in a company on the main market. All companies with shares traded on First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399.

Annual Report

  November 3, 2016
  Quarterly Report II, April 5, 2017

Dear Shareholders and readers

We recently decided to announce an aggressive rights issue of 68 MSEK to conduct a pivotal phase II trial, DIAGNODE-2, based on intralymphatic administration of Diamyd®. The decision is based on the very positive preliminary results from the ongoing investigator initiated DIAGNODE-1 trial, also recently published in the New England Journal of Medicine, as well as on the previously published meta- analysis of previous clinical trials with our vaccine showing that Diamyd® with a 98% likelihood has a positive biological effect. The decision is...

Our discussions with major multinational companies continue, and the established path forward with our GAD and GABA projects has created a significantly stronger negotiation position.
Ulf Hannelius, President and CEO

Calendar

 Dates for financial information and other events
June 9, 2017
ADA Scientific Sessions
American Diabetes Association 77th Scientific Sessions, San Diego, USA
June 28, 2017
Quarterly Report III
Quarterly Report 3 2016/2017
October 11, 2017
Financial Statement
Financial Statement 2016/2017
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 31, 2017

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 1 278 112 3 666 521 16.8 40.1
Avanza Pension 3 949 337 13.4 9.6
Lindkvist, Bertil 3 793 040 12.9 9.3
Nordnet Pensionsförsäkring AB 941 318 3.2 2.3
Swedbank Försäkring 521 335 1.8 1.3
Försäkrings AB Skandia 271 138 0.9 0.7
Relbo AB 237 776 0.8 0.6
Bohlin, Lennart 211 842 0.7 0.5
Arandi Development 210 000 0.7 0.5
Waldolf, Ann-Christin 198 666 0.7 0.5
Remaining shareholders 14 213 477 48.1 34.6
Total 1 278 112 28 214 450 100.0 100.0